Intellia Jumps on Test Announcement
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing Wednesday. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a…